Milprazon Chewable (4 - 8 kg)

12 x 4 pc

Film-coated tablet

Active substance

Praziquantel : 40 mg

Milbemycinoxim : 16 mg

ATC code

QP54AB51 Milbemycin oxime, comb.

QP54AB Milbemycins

QP54A Macrocyclic lactones

QP54 Endectocides

QP Antiparasitic products, insecticides and repellents

Species

Cats (weighing at least 2 kg).

Indications

Treatment of mixed infections by immature and adult cestodes and nematodes of the following species:

- Cestodes: Dipylidium caninum Taenia spp.

Echinococcus multilocularis

- Nematodes:

Ancylostoma tubaeforme

Toxocara cati

Prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.

Dose to be administered and administration route

Oral use.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given orally as a single dose. The veterinary medicinal product should be administered with or after some food. Doing so ensures optimum protection against heartworm disease.

Depending on the bodyweight of the cat, the practical dosing is as follows:

Body weight	Film-coated tablets for cats
2 - 4 kg	½ tablet
> 4 - 8 kg	1 tablet
> 8 - 12 kg	1½ tablets

The veterinary medicinal product can be inserted into a programme for prevention of heartworm disease if at the same time treatment against tapeworms is indicated. For the prevention of heartworm disease: the veterinary medicinal product kills Dirofilaria immitis larvae up to one month after their transmission by mosquitoes. For regular prevention of heartworm disease the use of a monosubstance is preferred.

Adverse reactions

Cats:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Hypersensitivity reaction;

Systemic disorders (e.g. lethargy)*;

Neurological disorders (e.g. ataxia and muscle tremors)*;

Digestive tract disorders (e.g. emesis and diarrhoea)*.

*Especially in young cats.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section 16 of the package leaflet for contact details.